[{"orgOrder":0,"company":"Annovis Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ANVS401","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buntanetap","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Buntanetap","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buntanetap","moa":"TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Posiphen tartrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Canaccord Genuity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"TFS Trial Form Support","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Annovis Bio \/ TFS Trial Form Support","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ TFS Trial Form Support"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buntanetap","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Annovis Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Not Applicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"APP\/Tau\/alpha SYN\/TDP43","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"AChE\/TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"AChE\/TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Buntanetap","moa":"AChE\/TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ ThinkEquity"},{"orgOrder":0,"company":"Annovis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Buntanetap","moa":"AChE\/TINAPs","graph1":"Neurology","graph2":"Phase III","graph3":"Annovis Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Annovis Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Annovis Bio \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Annovis Bio
Details :
ANVS401 (buntanetap), formerly known as Posiphen, is an oral small molecule. It is a translational inhibitor of TINAPs being investigated to treat alzheimer’s disease.
Details :
The net proceeds from the offering will be used to fund the clinical development of ANVS401 (buntanetap). It is being evaluated for the treatment of Parkinson Disease.
Details :
The net proceeds from the offering will be used to fund the clinical development of ANVS401 (buntanetap). It is being evaluated for the treatment of Parkinson Disease.
Details :
The Company intends to use the net proceeds for clinical development of ANVS401 (buntanetap), a novel translational inhibitor of multiple neurotoxic proteins, for the treatment of alzheimer's disease.
Details :
ANVS401 (buntanetap), formerly known as Posiphen, is an oral small molecule. It is a translational inhibitor of TINAPs being investigated to treat alzheimer’s disease and parkinson’s disease.
Details :
ANVS401 (buntanetap) attacks neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, thereby improving synaptic transmission in patients with Alzheimer’s Disease.
Details :
ANVS401 (buntanetap), formerly known as Posiphen, is an oral small molecule. It is a translational inhibitor of TINAPs being investigated to treat alzheimer’s disease and parkinson’s disease.
Details :
ANVS401 (buntanetap) works by inhibiting the formation of multiple neurotoxic proteins - amyloid beta, tau, alpha synuclein, and TDP43. It is being developed for mild to moderate Alzheimer’s disease.
Reset All
